Microsoft word - literatuurlijst-interacties-hansiem.doc
Referenties bij Mogelijke interacties tussen voedingssupplementen en antistollingsmiddelen? door drs. H. Siem
1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its
drug and food interactions. Arch Intern Med. 2005;165:1095–1106.
2. Haines ST, Zeolla M, Witt DM. Venous Thromboembolism. In: DiPiro JT, Talbert RL,
Yee GC, Matzke GR, Wel s BG, Posey LM. Pharmacotherapy: A Pathophysiological
Approach. 6th ed. New York: McGraw-Hil Companies, Inc.; 2005:373-413.
3. Micromedex Healthcare Series. Drug-REAX System. New York: Thomson Reuters;
4. Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's
effect in healthy patients: a randomized, controlled Trial. Ann Intern Med 2004;141(1):23-27.
5. JiangX, Wil iams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC et al. Effect of StJohn's
wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarinin healthy
subjects. Br J Clin Pharmacol 2004;57(5):592-599. View Abstract
6. What to do when warfarin therapy goes too far-Shailendra Prasad, MBBS,MPH; Department of
Family Medicine and Community Health, University of Minnesota
7. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting
the risk of major bleeding in outpatients treated with warfarin. Am J
8. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international
normalized ratio more rapidly than subcutaneous vitamin K in the treatment of
warfarin-associated coagulopathy. A randomized, control ed trial. Ann Intern
9. Fan J, Armitstead JA, Adams AG, et al. A retrospective evaluation of vitamin K1
therapy to reverse the anticoagulant effect of
warfarin. Pharmacotherapy. 2003;23:1245–1250.
10. Ansel J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K
antagonists. Chest. 2008;133(suppl):160S–198S.
11. Micromedex Healthcare Series. Drug-REAX System. New York: Thomson Reuters;
12. Interaction between warfarn and coenzyme Q10; Landbo C,Almdal TP.Hvidovre
13. CBO. Diagnostiek, Preventie en Behandeling van veneuze trombo-embolie en
secundaire preventie arteriële trombose. Utrecht, 2009. www.diliguide.nl
14. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of
aspirin: meta-analysis. BMJ 2000; 321: 1183-7
15. van Geest-Daalderop JHH, Sturk A. Omvang en kwaliteit van de
antistollingsbehandeling met coumarinederivaten door de Nederlandse
16. Reduces effect of warfarin caused by ubidecarenone. the Lancet 1994 Nov 12; 344
17. Holbrook AM, Pereira JA et al. Systematic overview of warfarin and its drug and
food interactions. Arch Intern Med. 2005; 165: 1095-1106
18. Commentaren Medicatiebewaking. 2011-2012. Stichting Healthbase.ISBN: 978-90-
19. Farmacotherapeutisch kompas 2012; http://www.fk.cvz.nl/
20. Natural Standard: http://naturalstandard.com/
21. Goodman @ Gilman 2011: Drug Toxicity and poisoning; Kevin Osterhoudt
22. Access Medicine. Principles of Clinical Pharmacology: Introduction
23. Clinical Pharmacokinetics 1980;Therapeutic response and toxicity
After either a referral by a recognized organization or contact via telephone or walk-in, the client will be placed on the waiting list. While on waiting list client wil participate in a screening process: an initial interview with a staff member to confirm criteria for entry and suitability. This is done either over the phone or in person. If individual is eligible, she will have to have these it
Landsdækkende klinisk retningslinje vedrørende udredning og behandling af depression hos børn og unge Vedtaget på BUP-DKs bestyrelsesmøde d. 11/10 - 2011 Retningslinjen bør revideres senest september 2013 Forfattere Merete Juul Sørensen, afdelingslæge, ph.d. Baggrund: BUP-DK har – i lighed med en lang række andre videnskabelige selskaber – besluttet at udgive